<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04305249</url>
  </required_header>
  <id_info>
    <org_study_id>ATG-017-001</org_study_id>
    <nct_id>NCT04305249</nct_id>
  </id_info>
  <brief_title>Safety and Preliminary Efficacy of ATG-017 Monotherapy in Advanced Solid Tumors and Hematological Malignancies</brief_title>
  <acronym>ERASER</acronym>
  <official_title>A Phase I, Open-Label, Multi-Center Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-017 Monotherapy in Patients With Advanced Solid Tumors and Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antengene Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antengene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multi-center, open-label study of ATG-017 administered orally, alone in&#xD;
      patients with advanced solid tumors and hematological malignancies. The study design includes&#xD;
      a Dose Escalation Phase and Dose Expansion Phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose escalation of ATG 017 with intensive safety monitoring to ensure the safety of the&#xD;
      patients with solid tumors (solid tumors group) and hematological malignancies (hematological&#xD;
      malignancies group) harbouring activating alterations in the RAS-MAPK pathway. Dose Expansion&#xD;
      Phase will begin at the defined maximum tolerated dose (MTD) and/or biologically effective&#xD;
      dose and/or other dose, in order to further evaluate the safety, tolerability and PDx of ATG&#xD;
      017. Patients with solid tumors or hematological malignancies harbouring activating&#xD;
      alterations in the RAS-MAPK pathway will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2020</start_date>
  <completion_date type="Anticipated">August 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs/SAEs</measure>
    <time_frame>18 months</time_frame>
    <description>Toxicity will be graded according to the NCI CTCAE, Version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations</measure>
    <time_frame>18 months</time_frame>
    <description>Venous blood samples for determination of total concentrations of ATG 017 in plasma to characterise the PK profile of ATG-017 for a particular dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>18 months</time_frame>
    <description>To determine the overall response rate according to RECIST1.1, Chenson 2014, IWG 2003 and 2006</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>18 months</time_frame>
    <description>Duration of time from first occurrence of CR or PR until the first date that disease progression is objectively documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>The time from the first dose date until disease progression or death from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Level of phospho-p90RSK</measure>
    <time_frame>18 months</time_frame>
    <description>Blood samples will be analysed for the level of phospho-p90RSK</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of transcript biomarker</measure>
    <time_frame>18 months</time_frame>
    <description>Blood samples will be analysed for the level of DUSP6</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of phospho-ERK</measure>
    <time_frame>18 months</time_frame>
    <description>Blood samples will be analysed for the level of phospho-ERK</description>
  </other_outcome>
  <other_outcome>
    <measure>Level of total ERK</measure>
    <time_frame>18 months</time_frame>
    <description>Blood samples will be analysed for the level of total ERK</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Hematological Malignancy</condition>
  <arm_group>
    <arm_group_label>ATG-017</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG-017 will be administered orally on an empty stomach QD in the first cohort of solid tumors group and BID 12 hours apart (no food or drink other than water for 2 hours prior to, and for 1 hour after study treatment administration) in other cohorts. All doses of ATG-017 should be taken at approximately the same time each day. Patients will receive study treatment in 21-day cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-017</intervention_name>
    <description>Dosing will begin at 5 mg once a day (QD) ATG-017 as starting dose. A cycle of study treatment will be defined as 21 days.</description>
    <arm_group_label>ATG-017</arm_group_label>
    <other_name>AZD0364 hemi-adipic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures, sampling and analyses.&#xD;
&#xD;
          2. Aged at least 18 years.&#xD;
&#xD;
          3. Patient must have a documented activating alteration of the RAS-MAPK pathway.&#xD;
&#xD;
          4. Histological or cytological confirmation of a solid tumour.&#xD;
&#xD;
          5. Patients with hematological malignancies.&#xD;
&#xD;
          6. Patient with solid tumors must have at least 1 lesion, not previously irradiated.&#xD;
&#xD;
          7. Estimated life expectancy of minimum of 12 weeks.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          9. Ability to swallow and retain oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Central nervous system metastatic disease, leptomeningeal disease, or metastatic cord&#xD;
             compression.&#xD;
&#xD;
          2. Prior ATG-017 administration in the present study.&#xD;
&#xD;
          3. Prior treatment with an ERK1/2 inhibitor.&#xD;
&#xD;
          4. Prior major surgery within 28 days of the first dose of study treatment or minor&#xD;
             surgical procedures â‰¤7 days.&#xD;
&#xD;
          5. Patients receiving unstable or increasing doses of corticosteroids.&#xD;
&#xD;
          6. As judged by the investigator, any evidence of severe or uncontrolled systemic&#xD;
             diseases.&#xD;
&#xD;
          7. Active infection including hepatitis B, and/or hepatitis C.&#xD;
&#xD;
          8. Known history of human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          9. Inadequate bone marrow reserve or organ function&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiao Kuang, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shimin Sun Sun, M.D.</last_name>
    <phone>021-23566665</phone>
    <email>jasmine.sun@antengene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leng Julia, M.Sc</last_name>
    <email>julia.leng@antengene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ben Tran</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jayesh Desai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Gan</last_name>
    </contact>
    <investigator>
      <last_name>Hui Gan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Voskoboynik</last_name>
    </contact>
    <investigator>
      <last_name>Mark Voskoboynik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scientia Clinical Research</name>
      <address>
        <city>Randwick</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Lemech</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Horvath</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

